• Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally
    • Cash position of €26.9 million as of June 30, 2022
    • Financial visibility assured until Q2 2023


    Paris (France), September 13, 2022 – 7:30 p.m. CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen[1]: ONXEO), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2022 and provides an update on its activities.

    [1] The company reminds shareholders that the delisting of Onxeo shares from the First North Growth market in Copenhagen has been approved and the last day of trading on this market will be November 8, 2022. The company will keep its primary listing on Euronext Growth Paris.